April Earnings Preview: Harvest Health & Trulieve
Harvest Health and Trulieve Both Report In The Next 24 Hours
This post intends to share analyst consensus estimates regarding metrics such as reported revenue and EBITDA, along with providing future updates which will include items such as the press release issued with the financials, the company's earnings deck, a link to the conference call webcast, a transcript of the conference call, the company's published MD&A and quarterly filing, and any other items of interest.
That being said, this resource will be updated on an ongoing basis to cover all of the aforementioned, alongside offering a Q-over-Q comparison surrounding certain metrics. In case you missed it, we published a similar write-up related to the recent releases by Curaleaf and Green Thumb Industries, which can be viewed here.
If you would like to learn more about each company, please click through their company logo to be taken to their investor profile page where we delve into specific details such as fully diluted market cap, share count, key quarterly financial metrics, and also extrapolate on their licenses by way of a highly-detailed footprint map. Lastly, if you're interested in looking at other data for Curaleaf, Green Thumb Industries, and all of the other companies - such as 'Last Quarter' and 'Q-over-Q' metrics - head over to our Visualizations page.
Revenue: Citing the company's organic growth - with no acquisitions closing in the quarter - the analyst consensus for Harvest's Q4 revenue rests at $40 million, a 21% increase quarter-over-quarter. EBITDA: With profitability likely similar to Harvest's Q3 results, analyst consensus for the company's Q4 EBITDA is ($9.5 million), with one analyst is projecting for ($13 million).
Revenue: Analysts are aligned with an anticipated revenue target of $78 million for Trulieve, which would be a +10% increase on a quarter-over-quarter basis. EBITDA: While the consensus is for Trulieve to generate $32 million in EBITDA - a 14% decline Q-over-Q inspired by the typically promotional Q4 period that brings about some pricing pressure - one analyst is forecasting for a beat to the tune of $36.5 million.
We rely on the gratitude of our readers to continue doing what we do best: create, curate, and share data-driven content on the top US-based cannabis outfits. If you would like to show your support, consider sharing the website with a friend, following us on Twitter, and signing up for our e-mail list.